Home Applications 219713 Application 219713
Type NDA
Sponsor NUVATION Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 IBTROZI TALETRECTINIB ADIPATE CAPSULE;ORAL EQ 200MG BASE Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N219713-001 IBTROZI TALETRECTINIB ADIPATE EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11
Orange Book patents# Current patent rows page 1 of 1 · 2 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 2 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N219713-001 NCE 2030-06-11 N219713-001 ODE-544 2032-06-11
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 c2088c7a36db…2026-09-14 22:38:34 2026-08 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 c2088c7a36db…2026-09-14 22:38:34 2026-08 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 a50c72e98297…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join IBTROZI TALETRECTINIB Nuvation Bio Inc. 51ac8e52-3269-4102-8dc8-dba22d82128c 2026-09-21 Warnings, Adverse reactions Exact identifier application applno (NDA): 219713 application number: NDA219713
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 82724 ORIG 2025-07-02 82557 ORIG 2025-06-12 82556 ORIG 2025-06-12